Loading...
NPI 1477076941 · Bristol, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Medarbor LLC is a clinical medical laboratory provider located in Bristol, Pennsylvania. This profile covers 62 Medicare and 109 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Medarbor LLC |
| Address | 200 Rittenhouse Circle East Building Suite 1 |
| City | Bristol |
| State | PA |
| ZIP | 19007 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 17, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $15.8M |
| Medicare | $12.3M |
Business/service-line profile: MEDARBOR LLC’s billing mix is heavily weighted to molecular infectious-disease testing and high-throughput SARS‑CoV‑2 diagnostics, as shown by large volumes on amplified nucleic acid probe codes (87798, 87481, 87799, 87640, 87653) and COVID-specific HCPCS U0004/U0005. The presence of many amplified-probe and multiplex pathogen codes indicates an operational focus on automated molecular platforms and centralized lab processing rather than low-volume point-of-care testing.
Medicare revenue concentration: MEDARBOR’s Medicare billing is highly concentrated—precomputed top 3 Medicare codes account for 67.9% of this provider's total Medicare revenue. The largest single Medicare driver is 87798 ($5.2M, 43.0% of Medicare revenue), followed by 87481 ($2.2M, 18.5%) and U0004 ($775.7K, 6.4%), and these codes together dominate its Medicare book of business.
Medicaid revenue concentration: MEDARBOR’s Medicaid billing is even more concentrated toward a few codes—precomputed top 3 Medicaid codes account for 75.3% of this provider's total Medicaid revenue. U0004 is by far the largest Medicaid line ($8.8M, 58.4% of Medicaid revenue), with U0005 ($1.3M, 8.6%) and 87798 ($1.2M, 8.3%) completing the top three, indicating Medicaid revenue is driven primarily by large-scale COVID testing.
Payer mix and scale: This provider reports lifetime Medicare revenue of $12.3M and lifetime Medicaid revenue of $15.8M, so Medicaid is the larger single payer in scale while the practice maintains substantial business with both payers. That dual-payer footprint combined with the concentration in a few molecular/COVID codes suggests its commercial strategy centers on volume testing across payers rather than a diversified procedural mix.
Competitive standing — Medicare: MEDARBOR shows outsized national presence on several molecular codes; 87798 ranks #7 of 1319 nationally and is labeled an extreme outlier, 87481 ranks #4 of 1117 (extreme outlier), and other codes like 87799 rank #2 of 246 (100th percentile; extreme outlier). These rankings indicate MEDARBOR is a major national volume player on specific molecular test codes for Medicare.
Competitive standing — Medicaid (in-state): In Medicaid, MEDARBOR is dominant statewide for core COVID and molecular codes: U0004 ranks #1 of 73 in-state (100th percentile; extreme outlier) and U0005 ranks #1 of 138 in-state (100th percentile; extreme outlier), with multiple other codes at or near #1 in-state. This pattern shows MEDARBOR is a leading in-state laboratory for high-throughput COVID testing and related molecular services.
Operational implication — specimen collection and throughput: High specimen-collection and processing volumes support the lab-scale interpretation: G2023 appears with 10.1K Medicare claims ($232K) and 68.1K Medicaid claims ($545.1K), and Medicaid U0004 volume alone is 182.9K claims generating $8.8M. Those counts and dollar figures are consistent with a centralized operation handling large batches of specimens and rapid-turnaround molecular testing.
Service breadth beyond COVID/molecular concentration: While molecular and COVID codes dominate revenue, Medicare and Medicaid claims also include culture (87086/87088), drug-testing (G0483/G0482/G0480), and multiplex panels (87631/87633/87506) at smaller shares, indicating MEDARBOR provides ancillary microbiology and toxicology services in addition to its core molecular testing. These secondary lines account for modest revenue relative to the concentrated top codes but demonstrate a broader technical capability set.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
62 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 153,290 | $30 | $5.2M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 65,800 | $30 | $2.2M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 10,480 | $70 | $775.7K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 12,730 | $40 | $534.8K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 14,810 | $30 | $503.4K |
| 87541 | The lab analyst performs a test for the bacteria Legionella pneumophila using amplified nucleic acid probe technique. L. pneumophila can inhabit facility water and air conditioning systems and may… | 14,230 | $30 | $483.8K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 12,700 | $30 | $431.9K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 8,070 | $30 | $274.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 10,200 | $30 | $254.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 10,090 | $20 | $232K |
Showing 1–10 of 62
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 62 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
62 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 2 | 40 | 1,250 | $30 | $1.1M |
| 87481 | 2 | 20 | 940 | $30 | $574.2K |
| 87653 | 2 | 20 | 360 | $30 | $175.8K |
| 87799 | 1 | 10 | 790 | $40 | $128.8K |
| U0004 | 1 | 10 | 190 | $70 | $105.8K |
| 87541 | 1 | 10 | 180 | $30 | $98.1K |
| 87529 | 11 | 10 | 80 | $30 | $96.6K |
| G0480 | 31 | 40 | 270 | $110 | $94.5K |
| 87500 | 2 | 30 | 110 | $30 | $94.4K |
| 87641 | 3 | 30 | 120 | $30 | $84.2K |
Showing 1–10 of 62
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
109 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 182,910 | $50 | $8.8M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 99,340 | $10 | $1.3M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 32,850 | $40 | $1.2M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 10,200 | $80 | $785.6K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 68,140 | $10 | $545.1K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 25,200 | $20 | $377.9K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 12,950 | $30 | $375.6K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 1,930 | $120 | $239.8K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 29,840 | $10 | $179.1K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7,550 | $20 | $143.5K |
Showing 1–10 of 109
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
109 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 29 | 130 | 310 | $60 | $769.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 34 | 210 | 730 | $40 | $689.7K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6 | 20 | 3,040 | $60 | $483.4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1 | 70 | 620 | $60 | $464.8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7 | 20 | 540 | $50 | $367.6K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 7 | 60 | 110 | $220 | $151.2K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 3 | 30 | 220 | $30 | $139.6K |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 7 | 10 | 4,750 | $1 | $133.9K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 65 | 80 | 420 | $100 | $130.6K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2 | 70 | 270 | $50 | $108.2K |
Showing 1–10 of 109
Other providers in the same ZIP code as Medarbor LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Skippack Medical Lab, LLC | PA | Clinical Medical Laboratory | $10.6M | $760.3K |
| Prime Healthcare Services Lower Bucks LLC | PA | General Acute Care Hospital | $0 | $8.7M |
| Mark Burton | PA | Primary Podiatric Medicine Podiatrist | $302.9K | $0 |
| Atul Trivedi | PA | Cardiovascular Disease Physician | $161.9K | $0 |
| Lester Libfraind | PA | Diagnostic Radiology Physician | $136.1K | $0 |
| Ramesh Adiraju | PA | Vascular Surgery Physician | $119.2K | $1.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.